Q2 EPS Estimates for VVOS Cut by Ascendiant Capital Markets

Posted by Stanley Muller on Jun 11th, 2026

Vivos Therapeutics, Inc. (NASDAQ:VVOS – Free Report) – Equities researchers at Ascendiant Capital Markets dropped their Q2 2026 EPS estimates for Vivos Therapeutics in a note issued to investors on Thursday, June 4th. Ascendiant Capital Markets analyst L. Ward now expects that the company will post earnings per share of ($0.54) for the quarter, down from their previous forecast of ($0.39). Ascendiant Capital Markets has a “Buy” rating and a $3.10 price objective on the stock. The consensus estimate for Vivos Therapeutics’ current full-year earnings is ($1.39) per share. Ascendiant Capital Markets also issued estimates for Vivos Therapeutics’ Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.52) EPS, FY2026 earnings at ($2.14) EPS and FY2027 earnings at ($2.17) EPS.

Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) last posted its quarterly earnings data on Wednesday, May 20th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.07). The company had revenue of $5.14 million for the quarter, compared to analysts’ expectations of $4.35 million. Vivos Therapeutics had a negative net margin of 127.70% and a negative return on equity of 2,325.64%.

Several other equities analysts also recently weighed in on the stock. HC Wainwright decreased their price target on shares of Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating on the stock in a research note on Friday, April 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $2.80.

Check Out Our Latest Research Report on VVOS

Vivos Therapeutics Stock Performance

VVOS opened at $0.64 on Thursday. The company has a quick ratio of 0.27, a current ratio of 0.27 and a debt-to-equity ratio of 3.31. The company has a market cap of $8.88 million, a price-to-earnings ratio of -0.30 and a beta of 6.10. Vivos Therapeutics has a 52-week low of $0.55 and a 52-week high of $7.95. The firm’s fifty day simple moving average is $0.87 and its two-hundred day simple moving average is $1.46.

Institutional Trading of Vivos Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Connective Capital Management LLC acquired a new stake in shares of Vivos Therapeutics during the 3rd quarter worth approximately $620,000. DRW Securities LLC increased its holdings in shares of Vivos Therapeutics by 179.5% during the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after buying an additional 74,441 shares during the last quarter. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Vivos Therapeutics during the 2nd quarter worth approximately $220,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Vivos Therapeutics during the 1st quarter worth approximately $28,000. Finally, XTX Topco Ltd acquired a new stake in shares of Vivos Therapeutics during the 2nd quarter worth approximately $65,000. Institutional investors and hedge funds own 26.35% of the company’s stock.

Insider Buying and Selling at Vivos Therapeutics

In other news, major shareholder Michael C. Skaff purchased 1,353,625 shares of the company’s stock in a transaction dated Tuesday, March 31st. The stock was acquired at an average price of $1.34 per share, with a total value of $1,813,857.50. Following the purchase, the insider directly owned 1,353,625 shares in the company, valued at approximately $1,813,857.50. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 2.10% of the company’s stock.

Vivos Therapeutics News Roundup

Here are the key news stories impacting Vivos Therapeutics this week:

Positive Sentiment: Vivos announced a collaboration with a multi-location Florida cardiology group to expand sleep apnea and insomnia diagnosis and treatment for cardiovascular patients, which could help widen its referral pipeline and support future growth. Article Title
Neutral Sentiment: Ascendiant Capital Markets kept a Buy rating and $3.10 price target on VVOS, but it also issued long-term earnings estimates that remain deeply negative, suggesting the stock still depends on a turnaround in profitability. Article Title
Negative Sentiment: Ascendiant lowered its Q2 2026, Q3 2026, Q4 2026, and FY2026 EPS estimates, signaling weaker near-term earnings expectations and adding to investor concerns about the company’s path to profitability. Article Title

About Vivos Therapeutics

(Get Free Report)

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.